Wes Weisbaum's HRT claims need some context
Quick answer
Hormone replacement therapy for transgender individuals typically involves testosterone for trans men or estrogen/anti-androgens for trans women. Discontinuation rates are low (2.9% in the largest study), with medical access barriers being more common reasons than regret. Supervised tapering is generally recommended over abrupt cessation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this video actually claim?
Wes Weisbaum (@wesweisbaum) argues that stopping hormone replacement therapy (HRT) doesn't automatically mean someone is detransitioning. He lists several reasons trans people might discontinue HRT: losing access, health concerns, cost barriers, not wanting to pass in a binary way, or choosing other forms of gender-affirming care.
His main point is that trans people aren't a monolith. Some never want HRT at all. The video aims to counter assumptions about why people stop hormones.
Does research support his claims about HRT discontinuation?
Yes, the limited research backs up Weisbaum's core points. A 2022 study by Ristori et al. in the Journal of Sex & Marital Therapy found that among 796 trans individuals, 2.9% discontinued hormone therapy. Only 0.4% cited regret about their gender identity as the reason.
The Coleman et al. Standards of Care Version 8 (2022) explicitly acknowledges that some trans people don't want medical interventions. A 2021 study by Turban et al. in LGBT Health found that among 27,715 trans adults, financial barriers affected hormone access for 25% of respondents.
Healthcare access issues are well-documented. D'Angelo et al. (2021) found that 33% of trans adults reported difficulty accessing hormone therapy due to provider shortages or insurance denials.
What context is missing from this video?
Weisbaum doesn't mention that some people do detransition, and research suggests rates vary widely depending on how you define it. Ristori's study found 0.4% detransitioned due to identity changes, but D'Angelo found 13.1% had ever detransitioned, with 82.5% of those later retransitioning.
The video also doesn't address that temporary discontinuation can have medical implications. Hormone withdrawal can cause mood changes, hot flashes, and other symptoms that patients should discuss with providers.
He's right that access barriers are real problems, but doesn't mention telehealth options that have expanded access for many people in underserved areas.
What should patients actually know about stopping HRT?
If you're considering stopping HRT for any reason, talk to your provider first. Abrupt cessation can cause withdrawal symptoms, and there might be ways to address your concerns without stopping entirely.
Financial assistance programs exist for many hormone medications. Some manufacturers offer patient assistance programs, and telehealth platforms have made treatment more affordable in many areas.
For health-related pauses, your provider might adjust dosing or switch formulations rather than stopping completely. Regular monitoring can help catch potential issues early.
Weisbaum is absolutely right that stopping HRT doesn't equal detransitioning. But whatever your reason for considering changes to hormone therapy, medical supervision makes the process safer.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Wes Weisbaum's HRT claims need some context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Wes Weisbaum's HRT claims need some context should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Hormone replacement therapy for transgender individuals typically involves testosterone for trans men or estrogen/anti-androgens for trans women.
FormBlends verdict
Hormone replacement therapy for transgender individuals typically involves testosterone for trans men or estrogen/anti-androgens for trans women. Discontinuation rates are low (2.9% in the largest study), with medical access barriers being more common reasons than regret. Supervised tapering is generally recommended over abrupt cessation.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Hormone replacement therapy for transgender individuals typically involves testosterone for trans men or estrogen/anti-androgens for trans women. Discontinuation rates are low (2.9% in the largest study), with medical access barriers being more common reasons than regret. Supervised tapering is generally recommended over abrupt cessation.
- Only 0.4% of trans people discontinue HRT due to gender identity regret, according to the largest study (Ristori et al., 2022)
- Financial barriers affect hormone access for 25% of trans adults (Turban et al., 2021)
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Only 0.4% of trans people discontinue HRT due to gender identity regret, according to the largest study (Ristori et al., 2022)
- Financial barriers affect hormone access for 25% of trans adults (Turban et al., 2021)
- 33% of trans adults report difficulty accessing hormone therapy due to provider or insurance issues
- The WPATH Standards of Care explicitly recognize that some trans people don't want medical interventions
- Detransition rates vary widely (0.4% to 13.1%) depending on how researchers define the term
- Supervised tapering is generally safer than abrupt HRT discontinuation
- Telehealth platforms and patient assistance programs have expanded access options for many patients
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Wes Weisbaum · Instagram creator
35.7K views on this video
🏳️⚧️ Not everyone who stops HRT is detransitioning. Some people lose access. Some need to pause for health. Some can’t afford it. Some do not seek to pass in a binary way. Some trans people don’t wa
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Wes Weisbaum, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.